# US 2008/0075734 A1 · Genetic Immunization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075734 A1
- Document ID: US20080075734A1
- Status: Published application
- Kind: A1
- Application number: 11/846,977
- Filed: 2007-08-29
- Published: 2008-03-27
- Earliest claimed: 2006-08-30
- Inventors: Zane Neal; Hans Herweijer
- Web page: https://patentgrep.com/patent/US20080075734A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/208: {IL-12}
- A61K 48/0016: {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 35/00: Antineoplastic agents
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Proper timing and combinatorial administration of immunocytokines and Flt3-L combined with vaccination with tumor associated antigens provides an anticancer therapeutic benefit. Sequential administration of GM-CSF after Flt3-L provides improved expansion of mature dendritic cell populations. The expansion of mature dendritic cells can be used to enhance an immune response in the subject.

## Claims

### Claim 1

A method for enhancing an immune response to a tumor in an animal comprising:
a) administering an effective dose of Fms-like tyrosine kinase ligand (Flt3-L) to the subject;
b) providing a time interval during which a population of immature dendritic cells is expanded in the subject;
c) administering, after the time interval of step b), an effective does of granulocyte-monocyte colony stimulating factor (GM-CSF),
d) administering an effective does of an immunocytokine to the subject; and,
e) administering an effective does of a tumor associated antigen to the subject.

### Claim 2

The method of step 1 wherein the time interval consists of about 5 to about 15 days.

### Claim 3

The method of step 1 wherein the time interval consists of about 8 to about 12 days.

### Claim 4

The method of step 1 wherein administering an effective dose of Flt3-L consists of delivering to the subject purified Flt3-L protein.

### Claim 5

The method of step 1 wherein administering an effective dose of Flt3-L consists of delivering to the subject a nucleic acid encoding the Flt3-L.

### Claim 6

The method of step 1 wherein administering an effective dose of GM-CSF consists of delivering to the subject purified GM-CSF protein.

### Claim 7

The method of step 1 wherein administering an effective dose of GM-CSF consists of delivering to the subject a nucleic acid encoding the GM-CSF.

### Claim 8

The method of step 1 wherein administering an effective dose of immunocytokine consists of delivering to the subject purified immunocytokine protein.

### Claim 9

The method of step 1 wherein administering an effective dose of immunocytokine consists of delivering to the subject a nucleic acid encoding the immunocytokine.

### Claim 10

The method of step 1 wherein administering an effective dose of tumor associated antigen consists of delivering to the subject purified tumor associated antigen protein.

### Claim 11

The method of step 1 wherein administering an effective dose of tumor associated antigen consists of delivering to the subject a nucleic acid encoding the tumor associated antigen.

### Claim 12 (depends on 1)

The method of claim 1 wherein the tumor associated antigen consists of a universal tumor associated antigen.

### Claim 13 (depends on 1)

The method of claim 1 wherein the immunocytokine comprises of IL12.
